PAC1 Receptor Antagonists for Fast-Acting Anxiety and Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant and anxiolytic drugs, such as SSRIs and BZDs, have limitations including slow onset of action, adverse reactions, and potential for dependency and withdrawal symptoms, while ketamine has safety concerns and mental side effects, necessitating a drug with a novel mechanism of action for treating treatment-resistant anxiety and depression.
Innovation Solution
Development of PAC1 receptor antagonist compounds PA-8 and PA-9 and their derivatives, which exhibit strong anti-anxiety and antidepressant effects in stress-induced animal models, offering a different mechanism of action than SSRIs and BZDs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRI is used for treatment, then antidepressant effect is achieved, but onset of action is slow (2-4 weeks) and adverse reactions occur
Solution Approach 1:
The patent changes the pharmacological parameter from serotonin reuptake inhibition (SSRI mechanism) to PAC1 receptor antagonism. This fundamental parameter change in the mechanism of action enables fast-acting antidepressant effects while avoiding the slow onset characteristic of SSRIs, as demonstrated by the rapid improvement in depressive behaviors in animal models within hours of administration
2Reliability
If BZD is used for treatment, then anxiolytic effect is achieved, but drug dependence and withdrawal symptoms occur
Solution Approach 1:
The patent changes the pharmacological target from benzodiazepine receptors to PAC1 receptors, fundamentally altering the mechanism of action. This parameter change eliminates the harmful effects of BZD such as drug dependence and withdrawal symptoms, while maintaining effective anxiolytic action through PAC1 receptor antagonism, as shown by the absence of dependence symptoms in preclinical studies
3Speed
If ketamine is used for treatment, then fast-acting antidepressant effect is achieved, but mental side effects and safety concerns occur
Solution Approach 1:
The patent changes the mechanism from NMDA receptor antagonism (ketamine) to PAC1 receptor antagonism. This parameter change preserves the fast-acting antidepressant effect (onset within hours) while eliminating the harmful mental side effects such as dissociation and psychosis that are characteristic of ketamine treatment
Solution Approach 2:
The patent converts the previously harmful PACAP signaling (which can contribute to stress responses) into a beneficial therapeutic effect by using PAC1 receptor antagonism. This transforms the PACAP system from a potential source of harm into a target that, when blocked, produces fast-acting antidepressant and anxiolytic effects without ketamine's side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide fast-acting and sustained anti-anxiety and antidepressant effects in pathological models without sedative side effects, effectively treating anxiety and depression with fewer adverse reactions.
Implementation Method 1
the compounds PA-8 and PA-9 and their derivatives have PAC1 receptor antagonistic action and analgesic action
Data Source
AI summary
This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II),wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group;or a salt thereof, or a solvate thereof.